| Code | CSB-RA024405MB1HU |
| Size | |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to AL-002, targeting TREM2 (Triggering Receptor Expressed on Myeloid cells 2), a critical immune receptor predominantly expressed on microglia in the central nervous system and peripheral myeloid cells. TREM2 plays an essential role in microglial survival, phagocytosis, and inflammatory response regulation. Loss-of-function mutations in TREM2 are associated with increased risk of Alzheimer's disease, frontotemporal dementia, and Nasu-Hakola disease, while TREM2 signaling influences microglial responses to amyloid plaques and neurodegeneration.
AL-002 is an investigational therapeutic antibody developed to enhance TREM2 function through agonistic mechanisms, promoting beneficial microglial activity in neurodegenerative conditions. This biosimilar provides researchers with a valuable tool for investigating TREM2-mediated pathways in neuroinflammation, microglial biology, and neurodegenerative disease models. It enables studies exploring immune modulation in the brain, microglial phagocytic capacity, and potential therapeutic strategies targeting innate immunity in neurological disorders.
There are currently no reviews for this product.